
    
      The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is
      being tested to treat people who have relapsed or refractory Hodgkin Lymphoma. This study
      will look at the overall response of people who took brentuximab vedotin.

      The study will enroll 60 patients. Participants received:

      â€¢ Brentuximab vedotin 1.8 mg/kg

      This multicenter trial is being conducted worldwide. The overall time to participate in this
      study is approximately 6 to 7 years. Participants will make multiple visits to the clinic,
      and will be contacted by telephone every 3 months for 18 months after the end of treatment
      (EOT) for follow-up assessment of overall survival and then every 6 months until death, study
      closure, or 5 years after enrollment of the last participant.
    
  